2016-2022年甘肃省无细胞百白破联合疫苗疑似预防接种异常反应监测分析  

Surveillance for adverse events following immunization of diphtheria,tetanus and acellular pertussis combined vaccine in Gansu,2016−2022

作　　者：刘舒瑜[1] 焦永卓[1] 梁雪枫[1] 张宁静[1] 安婧[1] 张晓曙[1] Liu Shuyu;Jiao Yongzhuo;Liang Xuefeng;Zhang Ningjing;An Jing;Zhang Xiaoshu(Gansu Provincial Center for Disease Control and Prevention,Lanzhou 730000,Gansu,China)

机构地区：[1]甘肃省疾病预防控制中心,甘肃兰州730000

出　　处：《疾病监测》2024年第8期965-969,共5页Disease Surveillance

基　　金：甘肃省卫生健康行业卫生科研计划项目(No.GSWSKY2021-018)。

摘　　要：目的 了解2016-2022年甘肃省吸附无细胞百白破联合疫苗(DTaP)接种后的疑似预防接种异常反应(AEFI)发生情况,并评价该疫苗的安全性。方法 通过中国免疫规划信息管理系统以及甘肃省预防接种管理信息系统分别收集甘肃省2016-2022年AEFI个案和接种数据,用描述性流行病学方法进行分析。结果 甘肃省2016-2022年共报告DTaP相关AEFI22 674例,报告发生率为259.24/10万剂。在AEFI病例中,一般反应占99.71%,男性多于女性(男女性别比为1.26∶1),18~24月龄(34.32%)和3~5月龄(33.35%)病例所占比例较多,与季节和月份无关(集中度M为0.17),不良反应主要发在接种后1 d内,异常反应以过敏性皮疹为主(48.48%),且近年来未发现异常反应可疑信号。结论 甘肃省DTaP安全性较好,AEFI反应预后良好,需继续加强AEFI监测工作,增强因果关联评估能力。Objective To understand characteristics of adverse events following immunization(AEFI)of diphtheria,tetanus and acellular pertussis(DTaP)combined vaccine in Gansu province from 2016 to 2022 and evaluate the safety of the vaccine.Methods The incidence data of AEFI and vaccination information were collected through the immunization planning information management system for a descriptive epidemiological analysis.Results A total of 22674 AEFI of DTaP vaccine were reported in Gansu from 2016 to 2022,the reported incidence of AEFI was 259.24/100000 doses.In AEFI cases,most reactions were general ones,accounting for 99.71%,and more boy babies were affected.The ratio of boy babies to girl babies is 1.26:1.And the cases aged 18-24 months(34.32%)and 3-5 months(33.35%)accounted for higher proportion.No seasonality and monthly distribution were observed(the concentration M is 0.17).The adverse reactions mainly occurred within 1 day after the vaccination.The abnormal reaction was mainly allergic rash(48.48%),and no suspicious signals of abnormal reactions were found in recent years.Conclusion DTaP is safe,and AEFI prognosis is good,it is necessary to further strengthen the surveillance for AEFI,and improve the capability of causal correlation assessment in Gansu.

关 键 词：无细胞百白破联合疫苗 疑似预防接种异常反应 监测 

分 类 号：R211[医药卫生—中医学] R186